FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the acceptance of a late-breaking abstract for presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting, which will be held in Prague, Czech Republic from April 10-13, 2024.
"Despite the availability of numerous immunosuppressive therapies, the unmet medical need remains high in lung transplantation, which has a 5-year mortality of approximately 50%. New targeted therapeutic approaches are clearly needed that can optimize immunosuppression in the lung while avoiding the dose-limiting toxicities associated with systemically administered immunosuppressive therapies," said Professor Gregory Snell, Medical Head of Lung Transplant Service at the Alfred Hospital and Lead Principal Investigator of the Phase 2 TFF TAC trial. "Initial data from the ongoing Phase 2 study suggest that TFF TAC, which delivers tacrolimus directly to the lungs, may represent a viable approach in achieving this desired balance, and I look forward to presenting initial data from the Phase 2 trial at the upcoming ISHLT 2024 meeting."
About TFF TAC
The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity. Part A of the trial is a 12-week treatment period, and Part B is an optional safety extension period. Trial endpoints include safety/tolerability, kidney function, and acute allograft rejection.
ABOUT TFF PHARMACEUTICALS' THIN FILM FREEZING (TFF) TECHNOLOGY
TFF Pharmaceuticals' proprietary TFF technology allows for the transformation of existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is ...